HGS-ETR2-ST02: A phase 1 clinical trial of HGS-ETR2, a fully-human activating monoclonal antibody to TRAIL-R2, in patients with advanced solid tumors.

被引：0
|
作者：
Sarantopoulos, J
Wakelee, H
Mita, M
Fitzgerald, A
Hill, M
Fox, NL
Howard, T
Ullrich, S
Tolcher, AW
Sikic, B
机构：
[1] Canc Therapy & Res Ctr S Texas, Inst Drug Dev, San Antonio, TX 78229 USA
[2] Stanford Univ, Sch Med, Stanford, CA 94305 USA
[3] Human Genome Sci Inc, Rockville, MD USA
来源：
CLINICAL CANCER RESEARCH | 2005年 / 11卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：9104S / 9104S
页数：1
相关论文
共 50 条
  • [1] HGS-ETR2 - A fully human monoclonal antibody to TRAIL-R2: Results of a phase I trial in patients with advanced solid tumors.
    Patnaik, A.
    Wakelee, H.
    Mita, M.
    Fitzgerald, A.
    Hill, M.
    Fox, N.
    Howard, T.
    Ullrich, S.
    Tolcher, A.
    Sikic, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 123S - 123S
  • [2] Phase I and pharmacokinetic study of HGS-ETR2, a fully human agonistic monoclonal antibody to TRAIL-R2, in patients with advanced solid malignancies.
    Attard, G
    Plummer, RE
    De Bono, JS
    Bale, C
    Fong, P
    Barrett, M
    Fox, NL
    Howard, T
    Ullrich, S
    Calvert, H
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9060S - 9060S
  • [3] Phase I and pharmacokinetic study of HGS-ETR2, a human monoclonal antibody to TRAIL R2, in patients with advanced solid malignancies.
    Pacey, S
    Plummer, RE
    Attard, G
    Bale, C
    Calvert, AH
    Blagden, S
    Fox, NL
    Corey, A
    de Bono, JS
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 205S - 205S
  • [4] Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors
    Wakelee, H. A.
    Patnaik, A.
    Sikic, B. I.
    Mita, M.
    Fox, N. L.
    Miceli, R.
    Ullrich, S. J.
    Fisher, G. A.
    Tolcher, A. W.
    ANNALS OF ONCOLOGY, 2010, 21 (02) : 376 - 381
  • [5] Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells
    Menoret, Emmanuelle
    Gomez-Bougie, Patricia
    Geffroy-Luseau, Alexandrine
    Daniels, Sylvanne
    Moreau, Philippe
    Le Gouill, Steven
    Harousseau, Jean-Luc
    Bataille, Regis
    Amiot, Martine
    Pellat-Deceunynck, Catherine
    BLOOD, 2006, 108 (04) : 1346 - 1352
  • [6] In vitro and in vivo effects after combined treatment of colorectal tumors with apoptosis inducing trail receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy
    Marini, P
    Denzinger, S
    Kauder, S
    Schiller, D
    Welz, S
    Jendrossek, V
    Budach, W
    Belka, C
    RADIOTHERAPY AND ONCOLOGY, 2006, 78 : S75 - S75
  • [7] Human agonistic anti-TRAIL receptor antibodies, HGS-ETR1 and HGS-ETR2, induce apoptosis in diverse hematological tumor lines.
    Johnson, RL
    Huang, XL
    Fiscella, M
    Cole, C
    Pukac, L
    Von Kerczek, A
    Humphreys, R
    Grzegorzewski, KJ
    Gallant, G
    Albert, V
    BLOOD, 2003, 102 (11) : 891A - 891A
  • [8] Treatment of colorectal tumors with apoptosis inducing TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 in combination with radiotherapy:: additive effects in vitro and dose dependent growth delay in vivo
    Marini, P.
    Schiller, D.
    Kauder, S.
    Denzinger, S.
    Welz, S.
    Jendrossek, V.
    Budach, W.
    Belka, C.
    EJC SUPPLEMENTS, 2005, 3 (02): : 45 - 45
  • [9] A phase 1 study of HGS-ETR1, a fully human agonistic monoclonal antibody to the TRAIL-R1, in combination with gemcitabine and cisplatin in subjects with advanced solid malignancies.
    Mom, CH
    Sleijfer, S
    Gietema, JA
    Sneller, V
    Fox, NL
    Lo, L
    Uges, DR
    Loos, W
    de Vries, EG
    Verweij, J
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9117S - 9117S
  • [10] Results of a phase 2 study of HGS-ETR1, a fully human agonistic monoclonal antibody to TRAIL Receptor 1, in subjects with relapsed or refractory colorectal cancer (CRC)
    Kanzler, S.
    Trarbach, T.
    Heinemann, V.
    Koehne, C. H.
    Sneller, V.
    Bieber, F.
    Galle, P. R.
    Seeber, S.
    EJC SUPPLEMENTS, 2005, 3 (02): : 178 - 178
12345